Regulatory

Oct 29, 2015
BioPharm International
In 2016, Amgen will simultaneously fight off biosimilar competitors to its legacy products and prepare to file its own follow-on products with regulators.
Oct 27, 2015
By BioPharm International Editors
The new committee will attempt to recruit regulatory professionals outside of existing ICH members to improve overall global pharmaceutical regulatory harmonization.
Oct 27, 2015
By BioPharm International Editors
The PRIME program is a drug development scheme to enable accelerated assessment of medications for conditions with unmet need.
Oct 14, 2015
Product labels should include more information on extrapolation, interchangeability, and the original source of clinical trial data, according to a survey of those in charge of dispensing medications.
Oct 08, 2015
Data protection for biologics is reduced from 12 to five years as a result of the Trans-Pacific Partnership agreement.
Sep 24, 2015
Although the presidential candidate seeks to cap monthly drug costs to $250 for covered drugs, what will happen to drug costs that are associated with co-insurance?
Sep 23, 2015
The presidential candidate teased the introduction of her drug-pricing plan on Twitter a day before she presented the details of her scheme to a community forum in Iowa.
Sep 15, 2015
BioPharm International
Manufacturers challenge details in new policies designed to promote access to important therapies.
Sep 01, 2015
By BioPharm International Editors
The agency started the full operation of its medical literature monitoring on Sept. 1, 2015.
Aug 27, 2015
In a new draft guidance, FDA proposes the use of a nonproprietary name plus a four-letter suffix to identify all biologic products, both new and old.
native1_300x100
lorem ipsum